(Q37830688)

24 August 2017

1 reference

title

Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review (English)

1 reference

cost-effectiveness analysis

24 August 2017

main subject

1 reference

1 reference

Maroeska M Rovers

5

0 references

Elisabeth Sanders

series ordinal

3

object named as

Elisabeth A M Sanders

1 reference

24 August 2017

4

Anne G M Schilder

1 reference

24 August 2017

author name string

Chantal W B Boonacker

series ordinal

1

1 reference

24 August 2017

Pieter H Broos

series ordinal

2

1 reference

24 August 2017

publication date

1 March 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

29

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

199-211

1 reference

Direct expenditures related to otitis media diagnoses: extrapolations from a pediatric medicaid cohort

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

Cost-effectiveness considerations in otitis media treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

New vaccines against otitis media: projected benefits and cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

The cost-effectiveness of pneumococcal conjugate vaccination in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

Cost Effectiveness of Pneumococcal Vaccination for Infants and Children with the Conjugate Vaccine PnC-7 in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

Epidemiological and economic burden of pneumococcal diseases in Canadian children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

The potential effect of widespread use of pneumococcal conjugate vaccines on the practice of pediatric otolaryngology: the case of acute otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584930-000000000-00000

Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001-2007.

21 January 2018

1 reference

12 December 2020

Epidemiology of acute suppurative otitis media

1 reference

12 December 2020

Antibiotic prescribing for Canadian preschool children: evidence of overprescribing for viral respiratory infections

1 reference

12 December 2020

[Acute otitis media in a pediatrics consulting office]

1 reference

12 December 2020

Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland

1 reference

12 December 2020

[Epidemiology and burden of acute otitis media in Valencia (Spain)]

1 reference

12 December 2020

Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea

1 reference

12 December 2020

Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain)

1 reference

12 December 2020

New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine

1 reference

12 December 2020

Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study

1 reference

12 December 2020

Increase in paediatric acute otitis media diagnosed by primary care in two Finnish municipalities--1994-5 versus 1978-9

1 reference

12 December 2020

Economic evaluation of pneumococcal conjugate vaccination in Finland

1 reference

12 December 2020

Postmarketing surveillance based on electronic patient records: the IPCI project

1 reference

12 December 2020

Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program

1 reference

12 December 2020

Estimating the cost-effectiveness of pneumococcal conjugate vaccination in Brazil

1 reference

12 December 2020

Incidence and impact of selected infectious diseases in childhood

1 reference

12 December 2020

Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina

1 reference

12 December 2020

Evolving microbiology and molecular epidemiology of acute otitis media in the pneumococcal conjugate vaccine era

1 reference

12 December 2020

10.2165/11584930-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

24 August 2017

1021883762

0 references

1 reference